Abstract：
This review aimed to systematically evaluate the immunogenicity and safety of the candidate Ebola virus vaccine (EVV).
We searched five databases for randomized controlled trials (RCTs) evaluating the effects of EVV on healthy adults. The primary outcomes were relative risk (RR) of sero-conversion or sero-response of EVV in healthy adults between the groups that received EVV and the controls.
Twenty-nine RCTs (n = 23573) were included. There was a significant difference in RR of sero-conversion of EVV (RR 13.18; 95% CI 11.28-15.41; I2 = 33%; P < 0.01) between the two groups. There was a significant difference in RR of adverse events (AEs) of EVV (RR 1.49; 95% CI 1.27-1.74; I2 = 88%; P < 0.01), although no difference in RR of serious AE (SAE) between the two groups. Subgroup analysis showed that there was no significant difference in RR of AEs for DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines, compared with controls.
The DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines are likely to be safe and immunogenic, tending to support the vaccination against Ebola disease. These findings should provide much-needed evidence for public health policy makers to develop preventive measures based on disease prevalence features and socio-economic conditions.
We searched five databases for randomized controlled trials (RCTs) evaluating the effects of EVV on healthy adults. The primary outcomes were relative risk (RR) of sero-conversion or sero-response of EVV in healthy adults between the groups that received EVV and the controls.
Twenty-nine RCTs (n = 23573) were included. There was a significant difference in RR of sero-conversion of EVV (RR 13.18; 95% CI 11.28-15.41; I2 = 33%; P < 0.01) between the two groups. There was a significant difference in RR of adverse events (AEs) of EVV (RR 1.49; 95% CI 1.27-1.74; I2 = 88%; P < 0.01), although no difference in RR of serious AE (SAE) between the two groups. Subgroup analysis showed that there was no significant difference in RR of AEs for DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines, compared with controls.
The DNAEBO, EBOV-GP, MVA, and rVSVN4CT1 vaccines are likely to be safe and immunogenic, tending to support the vaccination against Ebola disease. These findings should provide much-needed evidence for public health policy makers to develop preventive measures based on disease prevalence features and socio-economic conditions.
摘要：
■这篇综述旨在系统评估候选埃博拉病毒疫苗（EVV）的免疫原性和安全性。
■我们搜索了五个数据库，用于评估EVV对健康成年人的影响的随机对照试验（RCT）。主要结果是接受EVV的组和对照组之间的健康成年人的EVV血清转换或血清反应的相对风险（RR）。
■包括29个RCT（n=23573）。两组EVV血清转换的RR差异有统计学意义（RR13.18；95％CI11.28-15.41；I2=33％；P<0.01）。EVV不良事件(AE)的RR差异有统计学意义(RR1.49;95%CI1.27-1.74;I2=88%;P<0.01),尽管两组之间严重AE（SAE）的RR没有差异。亚组分析显示，DNAEBO的不良事件RR无显著差异，EBOV-GP,MVA,和rVSVN4CT1疫苗，与对照组相比。
■DNAEBO，EBOV-GP,MVA,rVSVN4CT1疫苗可能是安全和免疫原性的，倾向于支持针对埃博拉病毒的疫苗接种。这些发现应为公共卫生政策制定者根据疾病流行特征和社会经济状况制定预防措施提供急需的证据。
■我们搜索了五个数据库，用于评估EVV对健康成年人的影响的随机对照试验（RCT）。主要结果是接受EVV的组和对照组之间的健康成年人的EVV血清转换或血清反应的相对风险（RR）。
■包括29个RCT（n=23573）。两组EVV血清转换的RR差异有统计学意义（RR13.18；95％CI11.28-15.41；I2=33％；P<0.01）。EVV不良事件(AE)的RR差异有统计学意义(RR1.49;95%CI1.27-1.74;I2=88%;P<0.01),尽管两组之间严重AE（SAE）的RR没有差异。亚组分析显示，DNAEBO的不良事件RR无显著差异，EBOV-GP,MVA,和rVSVN4CT1疫苗，与对照组相比。
■DNAEBO，EBOV-GP,MVA,rVSVN4CT1疫苗可能是安全和免疫原性的，倾向于支持针对埃博拉病毒的疫苗接种。这些发现应为公共卫生政策制定者根据疾病流行特征和社会经济状况制定预防措施提供急需的证据。
